Abbott Laboratories (ABT)
(Real Time Quote from BATS)
$112.85 USD
-0.25 (-0.22%)
Updated Aug 28, 2024 11:24 AM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Abbott (ABT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$125.26 | $143.00 | $107.00 | 10.75% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Abbott comes to $125.26. The forecasts range from a low of $107.00 to a high of $143.00. The average price target represents an increase of 10.75% from the last closing price of $113.10.
Analyst Price Targets (19)
Broker Rating
Abbott currently has an average brokerage recommendation (ABR) of 1.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, 14 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 9.52% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 9.52%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ABT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 14 | 14 | 14 | 14 | 14 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 5 | 5 | 5 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.57 | 1.57 | 1.57 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/22/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/30/2024 | Edward D. Jones & Company | John Boylan | Hold | Hold |
7/29/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/24/2024 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
7/19/2024 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
6/11/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Strong Buy |
4/24/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
4/18/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/4/2024 | Evercore Partners | Vijay Kumar | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/2/2024 | Not Identified | Not Identified | Hold | Hold |
2/1/2024 | UBS | Danielle Antalffy | Strong Buy | Strong Buy |
1/19/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
10/18/2023 | Not Identified | Not Identified | Hold | Hold |
10/17/2023 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.57 |
ABR (Last week) | 1.57 |
# of Recs in ABR | 21 |
Average Target Price | $125.26 |
LT Growth Rate | 8.60% |
Industry | Medical - Products |
Industry Rank by ABR | 98 of 253 |
Current Quarter EPS Est: | 1.20 |